A Phase 2/3 interventional study of Alogliptin and metformin and Alogliptin and metformin in Type 2 Diabetes Mellitus, sponsored by Takeda. Completed. Open to participants aged 26 Years to 64 Years. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Takeda · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment, is one of 4 that started in 2008, is one of 7 in phase 2/3, and was the 23rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 26 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 23 · Phase 4 9
First in 2005; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 288 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 329 across the 39 interventional studies. Of the 35 that completed or were terminated, 30 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 52nd largest by enrollment of the 85 interventional ones that give a count, is one of 8 that started in 2008, is one of 7 in phase 2/3, and was the 58th registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.
Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.
The present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to metformin in type 2 diabetic patients who have uncontrolled blood glucose despite treatment with metformin as well as diet and exercise therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Alogliptin and metformin
Drug: Alogliptin and metformin
Drug: Metformin
Drug pages: Alogliptin · Metformin
Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
Also known as: SYR-32, Glycoran
Drug pages: Alogliptin · Metformin
Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
Also known as: SYR-322, Glycoran
Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
Also known as: Glycoran
Change From Baseline in Glycosylated Hemoglobin (Week 12).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
Time frame: Baseline and Week 12.
Change From Baseline in Glycosylated Hemoglobin (Week 2).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
Time frame: Baseline and Week 2.
Change From Baseline in Glycosylated Hemoglobin (Week 4).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
Time frame: Baseline and Week 4.
Change From Baseline in Glycosylated Hemoglobin (Week 8).
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
Time frame: Baseline and Week 8.
Change From Baseline in Fasting Plasma Glucose (Week 2).
The change between the value of fasting plasma glucose collected at week 2 and baseline.
Time frame: Baseline and Week 2.
Change From Baseline in Fasting Plasma Glucose (Week 4).
The change between the value of fasting plasma glucose collected at week 4 and baseline.
Time frame: Baseline and Week 4.
Change From Baseline in Fasting Plasma Glucose (Week 8).
The change between the value of fasting plasma glucose collected at week 8 and baseline.
Time frame: Baseline and Week 8.
Change From Baseline in Fasting Plasma Glucose (Week 12).
The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.
Time frame: Baseline and Week 12.
Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.
Time frame: Baseline and Week 12.
Participants enrolled at 30 investigative sites in Japan from 22 August 2008 to 28 April 2009.
| Milestone | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Started | 92 | 96 | 100 |
| Completed | 91 | 93 | 100 |
| Not completed | 1 | 3 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Schedule conflict | 0 | 1 | 0 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
| percentage of Glycosylated Hemoglobin | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | -0.54 ± 0.562 | -0.64 ± 0.488 | 0.21 ± 0.641 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
| percentage of Glycosylated Hemoglobin | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 2). | -0.13 ± 0.196 | -0.13 ± 0.150 | 0.06 ± 0.197 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
| percentage of Glycosylated Hemoglobin | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 4). | -0.29 ± 0.279 | -0.31 ± 0.268 | 0.09 ± 0.302 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
| percentage of Glycosylated Hemoglobin | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | -0.49 ± 0.488 | -0.56 ± 0.404 | 0.13 ± 0.465 |
The change between the value of fasting plasma glucose collected at week 2 and baseline.
| mg/dL | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (Week 2). | -19.2 ± 21.10 | -23.2 ± 24.17 | 0.0 ± 26.37 |
The change between the value of fasting plasma glucose collected at week 4 and baseline.
| mg/dL | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (Week 4). | -19.8 ± 25.28 | -23.5 ± 26.05 | -2.2 ± 23.37 |
The change between the value of fasting plasma glucose collected at week 8 and baseline.
| mg/dL | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (Week 8). | -22.0 ± 23.05 | -21.3 ± 25.30 | -3.1 ± 26.23 |
The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.
| mg/dL | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (Week 12). | -19.0 ± 23.23 | -23.1 ± 27.84 | -0.8 ± 32.20 |
The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.
| mg/dL | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12). | 61.7 ± 43.42 | 64.2 ± 34.76 | 70.6 ± 35.31 |
Collected over Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | — | 0/92 (0%) | 32/92 (34.8%) |
| Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | — | 2/96 (2.1%) | 37/96 (38.5%) |
| Metformin 500mg BID or 750mg TID | — | 0/100 (0%) | 29/100 (29%) |
| Event | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 1/96 | 0/100 |
| Mallory-Weiss syndromeGastrointestinal disorders | 0/92 | 1/96 | 0/100 |
| Event | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/92 | 22/96 | 20/100 |
| HeadacheNervous system disorders | 6/92 | 0/96 | 0/100 |
| DiarrhoeaGastrointestinal disorders | 5/92 | 1/96 | 1/100 |
| ConstipationGastrointestinal disorders | 1/92 | 4/96 | 2/100 |
| Conjunctivitis allergicEye disorders | 1/92 | 3/96 | 1/100 |
| Abdominal discomfortGastrointestinal disorders | 1/92 | 3/96 | 1/100 |
| Hepatic steatosisHepatobiliary disorders | 0/92 | 3/96 | 1/100 |
| Blood lactic acid increasedInvestigations | 0/92 | 1/96 | 3/100 |
| Age Continuous(years) | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID | Total |
|---|---|---|---|---|
| Mean | 53.4 ± 8.80 | 52.3 ± 8.02 | 52.1 ± 8.05 | 52.6 ± 8.28 |
| Sex: Female, Male(Participants) | Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID | Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID | Metformin 500mg BID or 750mg TID | Total |
|---|---|---|---|---|
| Female | 32 | 30 | 28 | 90 |
| Male | 60 | 66 | 72 | 198 |
No study locations are listed for this record.
The record gives a start of Aug 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alogliptin · Metformin